RJA
MRTX

Raymond James & Associates’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Raymond James & Associates’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,776
Closed -$228K – 4264
2022
Q1 		$228K Buy
2,776
+73
+3% +$7.46K ﹤0.01% 3596
2021
Q4 		$397K Sell
2,703
-1,234
-31% -$192K ﹤0.01% 3260
2021
Q3 		$696K Buy
3,937
+2,327
+145% +$374K ﹤0.01% 2821
2021
Q2 		$260K Sell
1,610
-4,748
-75% -$762K ﹤0.01% 3531
2021
Q1 		$1.09M Buy
6,358
+210
+3% +$41.6K ﹤0.01% 2451
2020
Q4 		$1.35M Sell
6,148
-93
-1% -$20.1K ﹤0.01% 2136
2020
Q3 		$1.04M Buy
6,241
+1,694
+37% +$232K ﹤0.01% 2156
2020
Q2 		$519K Buy
4,547
+110
+2% +$10.7K ﹤0.01% 2557
2020
Q1 		$341K Sell
4,437
-653
-13% -$58.6K ﹤0.01% 2688
2019
Q4 		$656K Buy
+5,090
New +$491K ﹤0.01% 2540
2019
Q3 		– Sell
-2,043
Closed -$210K – 3743
2019
Q2 		$210K Buy
+2,043
New +$159K ﹤0.01% 3222

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Raymond James & Associates's MRTX Position: Q2 2022 in Review

Raymond James & Associates sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 2,776 shares — an estimated $228K sold.

Raymond James & Associates first reported a position in MRTX in Q2 2019 and held it in 11 quarters. The position peaked at $1.35M in Q4 2020. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

  • Raymond James & Associates reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Raymond James & Associates sold 2,776 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $228K.
  • Raymond James & Associates first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 11 quarters.
  • Raymond James & Associates's Mirati Therapeutics, Inc. Common Stock position peaked at $1.35M in Q4 2020.
  • 230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.